Key considerations and common adverse events for HIV-positive patients with cancer treated with immune checkpoint inhibitors.
Emre YekedüzGüngör UtkanYuksel UrunPublished in: Future oncology (London, England) (2022)
HIV-infected patients are more susceptible to cancer due to their immune-compromised condition and HIV infection. Chronic inflammation and immune dysregulation are the main causes of cancer development in these patients. Because of lymphopenia and an immune-compromised condition, most HIV-infected patients with cancer were not considered for cytotoxic therapies, such as chemotherapy and radiotherapy. Immune checkpoint inhibitors (ICIs) have become a game-changer in many cancer types. However, not enough prospective data is available regarding the use of ICIs in HIV-infected patients with cancer. Retrospective data from case reports/series showed that ICIs are safe in HIV-infected patients with cancer.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv infected patients
- hiv positive
- human immunodeficiency virus
- papillary thyroid
- squamous cell
- newly diagnosed
- electronic health record
- oxidative stress
- end stage renal disease
- big data
- squamous cell carcinoma
- radiation therapy
- locally advanced
- childhood cancer
- cross sectional
- men who have sex with men
- case report
- deep learning